Selección de publicaciones

  • DNX-2401, an oncolytic virus, for the treatment of newly diagnosed diffuse intrinsic pontine gliomas: a case report. Tejada S, Díez-Valle R, Patiño-García A, González-Huarriz M, Fueyo J, Gomez-Manzano C, Idoate MA, Peterkin J, Alonso MM. Front Oncol. 2018 Mar 12;8:61. Doi 10.3389/fonc.2018.00061. eCollection 2018

  • Phase I trial of DNX-2401 for diffuse intrinsic pontine glioma newly diagnosed in pediatric patients. Tejada S, Alonso M, Patiño A, Fueyo J, Gomez-Manzano C and Diez-Valle R. Neurosurgery. 2017, Oct 27. doi: 10.1093/neuros/nyx507

  • Phase 1 Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya RE, Weinberg JS, Prabhu SS, Rao G, Fuller GN, Aldape KD, Gumin J, Vence L, Wistuba I, Rodriguez-Canales J, Villalobos PA, Dirven C, Tejada S, Diez Valle R, Alonso MM, Ewald B, Peterkin JJ, Tufaro F, and Fueyo J. J Clin Oncol. 2018 36(14):1419-1427.

  • The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma. Aldave G, Gonzalez-Huarriz, M, Rubio A, Romero JP, Ravi D, Miñana B, Cuadrado-Tejedor M, García-Osta A, Verhaak R, Xipell E, Martinez-Vélez N, Acanda de la Rocha A, Puigdelloses M, García-Moure M, Marigil M, Gállego Pérez-Larraya J, Marín-Bejar O, Huarte M, Carro MS, Ferrarese R, Belda-Iniesta C, Ayuso A, Prat-Acín R, Pastor F, Díez-Valle R, Tejada-Solis S and Alonso MM. NeuroOncol doi: 10.1093/neuonc/noy007

  • Yolanda González-Fernández, Hannah K. Brown, Ana Patiño-García, Dominique Heymann, María J. Blanco-Prieto. Oral administration of edelfosine encapsulated lipid nanoparticles causes regression of lung metastases in pre-clinical models of osteosarcoma. Cancer Letters 2018;430:193–200. I.I. 6.375 (Q1, 25/217, ONCOLOGY).

  • Machiela M, Grunewald T, Surdez D, Reynaud S, Mirabeau O, Karlins E, Rubio R, Zaidi S, Grossetête-Lalami S, Ballet S, Lapouble E, Laurence V, Michon J, Pierron G, Kovar H, Gaspar N, Kontny U, Gonzalez-Neira A, Picci P, Alonso J, Patiño-Garcia A, Corradini N, Marec Bérard P, Freedman N, Rothman N, Dagnall C, Burdett L, Jones K, Manning M, Wyatt K, Zhou W, Yeager M, Cox D, Hoover R, Khan J, Armstrong G, Leisenring W, Bhatia S, Robison L, Kulozik A, Kriebel J, Meitinger T, Metzler M, Hartmann W, Strauch K, Kirchner T, Dirksen U, Morton L, Mirabello L, Tucker M, Tirode F, Chanock S, Delattre O. Genome-wide association study identifies multiple new loci associated with ewing sarcoma susceptibility. Accepted for publication in Nature Communications. I.I. 12.124 (Q1, 3/64, MULTIDISCIPLINARY SCIENCES).

  • Manterola L, Guruceaga E, Gállego Pérez-Larraya J, Gonzalez-Huarriz M, Jauregui P, Segura V, Sampron N, Barrena C, Ruiz I, Tejada S, Diez-Valle R, Agirre A, Ayuso A, Rodriguez J, Gonzalez A, Matheu A, Tuñon T, Zazpe I, Xipell E, Lopez de Munain A, García-Foncillas J, Paris S, Delattre JY, Alonso MM. A sncRNA signature found in microvesicles of GBM patient serum serves as a diagnostic marker. Neuro Oncology. 2014 16:520-7. Highlighted in Nature Reviews Neurology (2014).

  • Martinez-Velez N, Xipell E, Jauregu P, Zalacain M, Marrodan L, Zandueta C, Vera B, Urquiza L, Sierrasesúmaga L, San Julián M, Toledo G, Fueyo J, Gomez-Manzano, C, Torre W, Lecanda F, Patiño-García A, Alonso MM. The oncolytic adenovirus Δ24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity J Bone Miner Res. 2014, 29:2287-96.

  • Martínez-Vélez N, Xipell E, Vera B, de la Rocha A, Zalacain M, Marrodán L, Gonzalez-Huarriz M, Toledo G, Cascallo M, Alemany R, Patiño A, Alonso MM. The oncolytic adenovirus VCN-01 as therapeutic approach against pediatric osteosarcoma. Clin Cancer Res 2016 May 1; 22(9):2217-25.

  • Xipell E, Aragón T, Martinez-Vélez N, Vera B, Idoate MA, Martínez-Irujo JJ, García-Garzón A, Gonzalez-Huarriz M, Acanda AM, Jones C, Lang FF, Fueyo J, Gomez-Manzano C and Alonso MM. ER-stress inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG and Rad51. Neuro Oncology 2016 Aug;18(8):1109-19.



"Nuestro laboratorio está interesado en desarrollar nuevas estratégias terapeúticas para tumores cerebrales infantiles y de adultos modulando el sistema inmune". Dra. Marta Alonso.

Contactar

Contacto:
Marisol Ripa
Avda. Pío XII, 55
31008 Pamplona
España

(+34) 948 194 700 Ext. 1010
msripa@unav.es